Jiangsu Aikon has been deeply engaged in the pharmaceutical R&D field for many years, ensuring rapid response to customer needs by providing fast delivery services for over ten thousand types of stock compounds and a wide range of synthetic customization services. Jiangsu Aikon not only saves valuable time for researchers and pharmaceutical companies but also significantly expands their options in the drug development process.

The analysis and testing center is equipped with comprehensive testing equipment and technology, which is key to ensuring product quality. In the pharmaceutical R&D field, even the slightest impurity or variation can have a major impact on the efficacy of the final product, making strict quality control indispensable. Jiangsu Aikon excels in this regard, with its testing equipment and technology providing a solid guarantee for product purity and quality.

Additionally, Jiangsu Aikon boasts a highly diverse product line, covering areas such as organic synthetic building blocks, pharmaceutical intermediates, general chemical reagents, and specialty chemicals. These products are not only varied in type but also available in a full range of specifications, from milligram to kilogram standard packaging, meeting diverse customer needs. This flexibility allows Jiangsu Aikon to better serve different types of customers and projects, whether it's new drug development for large pharmaceutical companies or scientific research for small institutions—all can find suitable products and services here.

In summary, Jiangsu Aikon has built a strong reputation in the pharmaceutical R&D field through its high-quality services, extensive product line, and robust testing system. They not only provide strong support for researchers and pharmaceutical companies but also make active contributions to advancing the pharmaceutical industry. It is believed that in the future, Jiangsu Aikon will continue to uphold its service philosophy of "quality first, customer foremost," bringing more high-quality products and services to the pharmaceutical R&D field.